Delegates including consultant gynaecologists, obstetricians and cytopathologists in the fields of surgical and diagnostics procedures gathered in Brussels last autumn for an Hologic user meeting.
Leading women’s health company Hologic (previously Cytyc) held its northern European annual user group meeting on 29–31 October in Brussels. A packed agenda saw presentations given by eminent guest speakers from the UK and Europe that discussed new product developments, informed and updated the latest research and trial results, and provided delegates with the opportunity to attend workshops and debate current topics.
A keynote speech was made Jack Cumming, Hologic chief executive officer, who welcomed 150 guests at a formal dinner that preceded the day’s events. Hologic is involved solely in women’s health and Mr Cumming explained that Cytyc and Hologic have combined under the Hologic name with a shared commitment to enhance women’s health through earlier and better detection, improved diagnosis, less-invasive treatments and improved patient outcomes. Hologic holds the number one position in nine technology areas serving women’s health, including breast cancer diagnosis and treatment, cervical cancer screening, treatment of menorrhagia, prenatal testing and osteoporosis detection.
Diagnostics agenda
The first day’s session opened with a look at the diagnostics agenda, chaired by Dr Euphemia McGoogan, Hologic’s European medical director. This covered updates and trial results from the Eindhoven trial that compared ThinPrep liquid-based cytology (LBC) cervical screening with conventional Papanicoloau slides in The Netherlands, presented by Dr Johan Bulten, a pathologist at the Radboud University Nijmegen Medical Centre.
Log in or register FREE to read the rest
This story is Premium Content and is only available to registered users. Please log in at the top of the page to view the full text.
If you don't already have an account, please register with us completely free of charge.